ArticleClinical interventions in aging2026
Frailty and an Inflammation-Nutrition Composite for Predicting Postoperative Outcomes in Older Patients Undergoing Endometrial Cancer Surgery.
Article in Clinical interventions in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Frailty and systemic inflammation/immune-protein reserve may drive adverse outcomes after endometrial cancer (EC) surgery in older patients, but their incremental predictive value is unclear. Methods: We analyzed a retrospective cohort of women ≥65 years undergoing primary EC surgery between January 2016 and December 2024. Frailty was assessed using mFI‑5. Inflammation-nutrition status (INS) was derived from routine preoperative laboratory tests as exploratory composite. The primary endpoint was 30‑day severe complications (Clavien-Dindo III-V), and the secondary endpoint was 90‑day unplanned readmission to the index hospital. One‑year non-endometrial cancer (non‑EC) death was exploratory with EC death as a competing event. Logistic regression and Fine-Gray models were fitted. Incremental prediction versus a prespecified baseline perioperative clinical model was evaluated with bootstrap optimism‑corrected discrimination, calibration, and decision‑curve analysis. Results: Severe complications occurred in 62 (7.1%) and readmission in 71 (8.1%). One‑year non‑EC and EC deaths were 28 (3.2%) and 19 (2.2%), respectively. mFI‑5 and INS predicted severe complications (OR per 1‑point mFI‑5 1.43 [95% CI 1.22-1.67]; OR per 1‑SD INS 1.34 [1.15-1.55]) and readmission (OR 1.28 [1.10-1.50]; OR 1.22 [1.05-1.41]). For non‑EC death, mFI‑5 (SHR 1.52 [1.23-1.88]) and INS (SHR 1.37 [1.11-1.69]) were significant. Adding mFI‑5+INS improved discrimination (AUC 0.69 to 0.77 for complications; 0.63 to 0.70 for readmission) and the time-dependent C-index for the exploratory competing-risk endpoint (0.66 to 0.73), with acceptable calibration. Decision-curve findings were descriptive rather than definitive. Conclusion: Combining frailty with an objective inflammation-nutrition risk composite modestly improved internal model performance for 30-day severe complications and 90-day readmission in older EC patients, and 1-year non-EC death analysis remains exploratory. These findings should be interpreted as perioperative rather than purely preoperative prediction, and decision thresholds require external validation before protocolized use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.